Skip to main content
森萱医药 logo

森萱医药 — Investor Relations & Filings

Ticker · 920946 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2022-08-28 Governance Information
Country CN China
Listing Beijing Stock Exchange 920946

About 森萱医药

https://www.senxuan.cn/

Jiangsu Senxuan Pharmaceutical Co., Ltd. specializes in the research, development, and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialized fine chemicals. The company’s product portfolio includes key intermediates for antiviral medications, such as those used in the treatment of HIV, and anticonvulsant agents like Primidone. Additionally, it produces high-purity chemical solvents including 1,4-dioxane and 1,3-dioxolane for diverse industrial applications. Senxuan Pharmaceutical maintains a focus on advanced chemical synthesis and large-scale manufacturing capabilities, adhering to international quality standards to support the global life sciences and chemical sectors. Its operations are characterized by a commitment to technical innovation and the supply of critical chemical building blocks for complex therapeutic formulations.

Recent filings

Filing Released Lang Actions
董事、监事和高级管理人员内部问责制度
Governance Information Classification · 95% confidence The document is a detailed internal accountability system for directors, supervisors, and senior management of Jiangsu Senxuan Pharmaceutical Co., Ltd. It outlines the principles, responsibilities, scope, forms, procedures, and enforcement of internal accountability within the company. There is no financial data, no mention of financial results, no regulatory filings or announcements about voting or dividends, and no indication of a report publication or earnings release. The document is a governance-related internal policy document, focusing on management and board accountability and internal control mechanisms. Therefore, it fits best under the category of Governance Information (CGR). The document length is 3228 characters, which is relatively short but contains substantive governance content rather than a mere announcement or certification.
2022-08-28 Chinese
独立董事年报工作制度
Governance Information Classification · 95% confidence The document is titled as an internal work system for independent directors related to the annual report process of Jiangsu Senxuan Pharmaceutical Co., Ltd. It outlines the responsibilities and procedures for independent directors in overseeing the annual report preparation and audit process. The document does not contain actual financial data or the annual report itself, but rather describes governance and procedural rules related to the annual report. It is a governance-related internal control document rather than a report or announcement of financial results. Therefore, it fits best under Governance Information (CGR). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2022-08-28 Chinese
2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告 2022" which translates to "Half-Year Report 2022". It contains detailed financial data including income, profit, assets, liabilities, cash flows, and operational highlights for the period January 1, 2022 to June 30, 2022. The content includes comprehensive financial statements, management discussion of financial results, risk disclosures, and operational updates. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of detailed accounting data and financial analysis confirms it is an interim or quarterly report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-28 Chinese
外部信息使用人管理制度
Governance Information Classification · 95% confidence The document is titled as an internal management system for external information users of Jiangsu Senxuan Pharmaceutical Co., Ltd. It details the company's policies and procedures regarding the handling of confidential information, insider trading prevention, and information disclosure compliance. The document includes references to board meeting resolutions and internal governance rules but does not contain financial data, earnings, audit results, or shareholder voting outcomes. It is a governance-related document focusing on internal rules and compliance rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR). The document length is short and does not indicate it is an announcement of a report publication, so it is not RPA or RNS.
2022-08-28 Chinese
内幕信息知情人报备制度
Regulatory Filings Classification · 95% confidence The document is a detailed internal information reporting system for insiders of Jiangsu Senxuan Pharmaceutical Co., Ltd. It outlines the company's insider information reporting procedures, definitions of insider information, scope of insiders, confidentiality rules, and reporting requirements to the Beijing Stock Exchange. There is no financial data, earnings information, or report publication. It is not an announcement of voting results, management changes, or legal proceedings. The document is a regulatory compliance disclosure related to insider information management and reporting, which fits best under Regulatory Filings (RNS). The document length is under 5,000 characters, but it is substantive and not merely an announcement of a report publication, so RPA is not appropriate. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2022-08-28 Chinese
独立董事关于第三届董事会第十六次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the independent directors of Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding their independent opinion on a board meeting held on August 26, 2022. The content focuses on the review and approval of a special report about the use and storage of raised funds for the period January to June 2022. It references compliance with regulatory requirements and confirms the legality and fairness of the procedures. The document is short (833 characters) and does not contain detailed financial statements or comprehensive financial data. It is an announcement of the independent directors' opinion on a specific agenda item discussed at a board meeting, rather than the report itself or a full financial report. This fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2022-08-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.